News > Health for Life Capital II announces its first close

Health for Life Capital II announces its first close

Sunday 24 March 2019

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, announces it has completed the first closing of its second dedicated fund focused on the microbiome, and health, nutrition and digital/connected health sectors, Health for Life Capital II, with a target for the final close of over €200 million.

Supported by prestigious corporate partners from food and pharma industry, Health for Life Capital II will keep its core focus on the microbiome, including platforms, drugs, nutritional solutions, diagnostics and biomarkers, as well as opportunistic investments in digital therapeutics, connected health, digital nutritional advice, personalised nutrition, precision medicine and food technologies.

HFL II has already committed to its first two investments: Axial Biotherapeutics in the US and Galecto Biotech in Denmark.

Contact | Conception | Site Map